Guardant Health (GH) news

Guardant Health: has validated Guardant360 design improvements

Guardant Health: current Guardant Reveal and Shield products excluded from final court order

A recent ruling by the 5th U.S. Circuit Court of Appeals has invalidated the formula used to calculate the "qualifying payment amount" (QPA) under the No Surprises Act, a 2020 law aimed at preventing patients from facing unexpectedly high medical bills for out-of-network care. The court found the…

Guardant Health to appeal federal district court judgment

Guardant Health, Inc. has announced its intention to appeal a recent federal district court judgment that ordered the company to pay $245.2 million to TwinStrand Biosciences and the University of Washington. The ruling, issued by the U.S. District Court for the District of Delaware on August 21,…

Guardant Health ordered to pay TwinStrand over $245.2M

A Delaware federal court jury has ordered Guardant Health to pay $83.4 million in damages to TwinStrand Biosciences and the University of Washington, finding that the company willfully infringed two patents related to DNA sequencing technology used in its cancer-testing kits. The verdict, issued in…

Canaccord Genuity raises target price to $135 from $130

Canaccord Genuity Group has raised its price target for Guardant Health (NASDAQ:GH) to $205 from $135, maintaining a "buy" rating for the stock, according to a recent research note. This adjustment reflects increased optimism among analysts regarding the company’s growth prospects. The firm’s…